null
ChEBI ID: 46851
Member | Definition | Role |
---|---|---|
acetophenazine | A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2. | acetophenazine |
dasatinib | An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN). | dasatinib (anhydrous) |
indinavir sulfate | indinavir | |
perphenazine | A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10. | perphenazine |
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 1,132 (19.08) | 18.7374 |
1990's | 755 (12.73) | 18.2507 |
2000's | 1,489 (25.10) | 29.6817 |
2010's | 1,901 (32.05) | 24.3611 |
2020's | 655 (11.04) | 2.80 |
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 787 (12.63%) | 5.53% |
Reviews | 494 (7.93%) | 6.00% |
Case Studies | 759 (12.18%) | 4.05% |
Observational | 25 (0.40%) | 0.25% |
Other | 4,168 (66.87%) | 84.16% |